Screener
Janux Therapeutics JANX Balance Sheet Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $27.77M-47.1% | $51.83M-29.7% | $52.33M-87.8% | $48.39M+80.9% | $52.45M+258% | ||
| $943.15M0.0% | $904.56M-3.8% | $914.23M+53.8% | $940.6M+49.0% | $943.57M+49.4% | ||
| $149K— | $35M— | $0— | —— | $0-100% | ||
| $983.34M-2.2% | $1B-2.1% | $975.89M-5.6% | $998.09M+49.8% | $1.01B+51.9% | ||
| $3.26M-30.5% | $3.55M-28.3% | $3.85M-20.8% | $4.31M-19.7% | $4.69M-21.1% | ||
| $1.01B-2.4% | $1.03B-2.1% | $1B-5.6% | $1.02B+47.4% | $1.03B+49.3% | ||
| $3.02M-13.2% | $3.38M+43.6% | $4.97M+23.5% | $3.4M+37.9% | $3.48M+177% | ||
| $35.07M— | $37.59M— | $0— | —— | —— | ||
| $60.15M+181% | $58.92M+237% | $25M+43.2% | $27.83M+62.1% | $21.38M+85.2% | ||
| $79.67M+91.1% | $86.69M+126% | $44.74M+15.5% | $48.21M+23.9% | $41.7M+23.6% | ||
| $61K+3.4% | $60K+1.7% | $60K+1.7% | $60K+15.4% | $59K+13.5% | ||
| -$397.72M-34.8% | -$375.74M-43.8% | -$351.38M-47.8% | -$319.44M-46.8% | -$295.12M-55.8% | ||
| $927.98M-6.3% | $941.54M-7.0% | $956.82M-6.4% | $976.56M+48.8% | $990.52M+50.6% | ||
| $1.01B-2.4% | $1.03B-2.1% | $1B-5.6% | $1.02B+47.4% | $1.03B+49.3% |
FAQ
- What are Janux Therapeutics's total assets?
- Janux Therapeutics (JANX) holds $1.0B in total assets, down 2.4% year over year.
- How much debt does Janux Therapeutics have?
- Janux Therapeutics carries $21.0M in total debt against $928.0M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Janux Therapeutics have?
- Janux Therapeutics holds $27.8M in cash and equivalents.
- Can Janux Therapeutics cover its short-term obligations?
- Its current ratio is 16.35 — current assets exceed current liabilities.
- Where does Janux Therapeutics's balance sheet data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
